The safety profile of drotrecogin alfa (activated)

Critical Care

Volumn 11, Issue SUPPL. 5, 2007, Pages

  Fumagalli, Roberto ^a,b   Mignini, Mariano A ^c  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Eli Lilly Italia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; ENOXAPARIN; HEPARIN; PLACEBO; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECCHYMOSIS; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEMATEMESIS; HEMATOMA; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; SURGICAL PATIENT; THROMBOSIS; UNITED STATES; ADULT; AGE; APACHE; CHEMICALLY INDUCED DISORDER; CHILD; DRUG CONTRAINDICATION; DRUG INTERACTION; MULTIPLE ORGAN FAILURE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURGICAL INFECTION;

ADULT; AGE FACTORS; ANTI-INFECTIVE AGENTS; APACHE; CHILD; DRUG INTERACTIONS; HEMORRHAGE; HEPARIN; HUMANS; MULTIPLE ORGAN FAILURE; PROTEIN C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RISK FACTORS; SEPSIS; SURGICAL WOUND INFECTION;

EID: 40649101641     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6157     Document Type: Review

References (34)

1. Marlar RA Kleiss AJ Griffin JH Human protein C: Inactivation of factors V and VIII in plasma by the activated molecule Ann N Y Acad Sci 1981, 370:303-310. 10.1111/j.1749-6632.1981.tb29743.x 6791548
2. Esmon CT The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway J Autoimmun 2000, 15:113-116. 10.1006/ jaut.2000.0400 10968895
3. Macias WL Yan SB Williams MD Um SL Sandusky GE Ballard DW Planquois JMS New insights into the protein C pathway: Potential implications for the biological activities of drotrecogin alfa (activated) Crit Care 2005, 9(Suppl 4):38-45. 10.1186/cc3747
4. Mosnier LO Griffin JH Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor Biochem J 2003, 373:65-70. 1223481 12683950 10.1042/BJ20030341
5. Mosnier LO Zlokovic BV Griffin JH The cytoprotective protein C pathway Blood 2007, 109:3161-3172. 10.1182/blood-2006-09-003004 17110453
6. US Food and Drug Administration Anti-Infective Drugs Advisory Committee Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)]: Xigris, bla 125029/0 http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3797b1.htm
7. European Medicines Agency Xigris: Product information http://www.emea.europa.eu/humandocs/Humans/EPAR/xigris/Xigris.htm
8. European Medicines Agency Xigris: Product information http://www.emea.eu.int/humandocs/PDFs/EPAR/xigris/H-396-PI-en.pdf
9. Short MA Schlichting D Qualy R From bench to bedside: A review of the clinical trial development of drotrecogin alfa (activated) Curr Med Res Opin 2006, 22:2525-2540. 10.1185/030079906X154060 17265595
10. Bernard GR Ely EE Wright TJ Fraiz J Stasek JE Jr Russell JA Mayers I Rosenfeld BA Morris PE Yan SB on behalf of the rhAPC Sepsis Study Group Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis Crit Care Med 2001, 29:2051-2059. 10.1097/00003246-200111000-00003 11700394
11. Bernard GR Vincent J-L Laterre P-F La Rosa SP Dhainaut J-F Lopez Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely W for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis PROWESS) Study Group Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001 11236773
12. Vincent J-L Bernard GR Beale R Doig C Putensen C Dhainaut J-F Artigas A Fumagalli R Macias WL Wright T for the ENHANCE Study Group Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment Crit Care Med 2005, 33:2266-2277. 10.1097/ 01.CCM.0000181729.46010.83 16215381
13. Abraham E Laterre P-F Garg R Levy H Talwar D Trzaskoma BL François B Guy JS Brückmann M Rea-Neto A for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935 16192478
14. Levi M Levy M Williams MD Douglas I Artigas A Antonelli M Wyncoll D Janes J Booth FV Wang D for the Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated) Am J Respir Crit Care Med 2007, 176:483-490. 10.1164/rccm.200612-1803OC 17556722
15. Sharshar T Annane D de la Grandmaison GL Brouland JP Hopkinson NS Francoise G The neuropathology of septic shock Brain Pathol 2004, 14:21-33. 14997934
16. Bernard GR Macias WL Joyce DE Williams MD Bailey J Vincent J-L Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis Crit Care 2003, 7:155-163. 270661 12720562 10.1186/cc2167
17. Rowan K Welch CA North E Harrison DA Multicenter audit of the use of drotrecogin alfa (activated) in United Kingdom critical care units [abstract 375] Intensive Care Med 2006, 32(suppl 1):99.
18. Vincent JL Laterre PF Janes J Nelson D Haentjens T Sartral M Ermens M Sundin D Analysis of drotrecogin alfa (activated) use in Belgium: comparison to PROGRESS registry data [abstract 227] Intensive Care Med 2005, 31(suppl 1):62.
19. Kübler A Mayzner-Zawadzka E Durek G Gaszyñski W Karpel E Mikaszewska Sokolewicz M Majak P Results of severe sepsis treatment program using recombinant human activated protein C in Poland Med Sci Monit 2006, 12:CR107-CR112. 16501420
20. Bertolini G Rossi C Anghileri A Livigni S Addis A Poole D Use of drotrecogin alfa (activated) in Italian intensive care units: The results of a nationwide survey Intensive Care Med 2007, 33:426-434. 10.1007/s00134-007-0554-x 17325836
21. Kanji S Perreault MM Chant C Williamson D Burry L Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: A Canadian multicenter observational study Intensive Care Med 2007, 33:517-523. 10.1007/s00134-007-0555-9 17325837
22. Barie PS Hydo LJ Shou J Eachempati SR Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis Surg Infect (Larchmt) 2006, 7(suppl 2):S77-S80. 16895513
23. Laterre P-F Wittebole X Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis - practical aspects at the bedside and patient identification Crit Care 2003, 7:445-450. 374360 14624684 10.1186/cc2342
24. Nadel S Goldstein B Williams MD Dalton H Peters M Macias WL Abd-Allah SA Levy H Angle R Wang D for the REsearching severe Sepsis and Organ dysfunction in children Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomized controlled trial Lancet 2007, 369:836-843. 10.1016/S0140-6736(07)60411-5 17350452
25. Mann HJ Demmon SL Boelk DA Payne CA Effron MB Rajagopalan N Williams MD Beck GM Gopalrathnam G Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration Am J Health Syst Pharm 2004, 61:2664-2671. 15646701
26. Lee SJ Schuster R Bindewald M Greaney G Waxman K Second course of recombinant human activated protein C delivered to a severely septic patient after recent surgery Trauma 2006, 61:1-3.
27. Oppenheim-Eden A Glantz L Eidelman LA Sprung CL Spontaneous intracerebral hemorrhage in critically ill patients: Incidence over six years and associated factors Intensive Care Med 1999, 25:63-67. 10.1007/ s001340050788 10051080
28. Vincent JL Drotrecogin alfa (activated) in the treatment of severe sepsis Expert Rev Anti Infect Ther 2006, 4:537-547. 10.1586/ 14787210.4.4.537 17009934
29. Warren BL Eid A Singer P Pillay SS Carl P Novak I Chalupa P Atherstone A Pénzes I Kübler A for the KyberSept Trial Study Group High-dose antithrombin III in severe sepsis. A randomized controlled trial JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869 11597289
30. Abraham E Reinhart K Opal S Demeyer I Doig C Lopez Rodriguez A Beale R Svoboda P Laterre P-F Simon S for the OPTIMIST Trial Study Group Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis. A randomized controlled trial JAMA 2003, 290:238-247. 10.1001/jama.290.2.238 12851279
31. Laterre PF Abraham E Janes J Trzaskoma BL Correll NL Booth FV ADDRESS (ADministration of Drotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation Crit Care Med 2007, 35:1457-1463. 10.1097/01.CCM.0000266588.95733.63 17452935
32. Williams MD Macias W Rustige J Safety of drotrecogin alfa (activated): A fair comparison requires consistent definitions Intensive Care Med 2007, 33:1487-1488. 10.1007/s00134-007-0709-9 17563878
33. Levi M Opal SM Coagulation abnormalities in critically ill patients Crit Care 2006, 10:222. 1750988 16879728 10.1186/cc4975
34. Plataki M Vaporidi K Georgopoulos D Is there increasing evidence that the risks of rhAPC may outweigh its benefits? Intensive Care Med 2007, 33:1485-1486. 10.1007/s00134-007-0707-y 17563880